Source check: Source checked. Not independent scientific confirmation.
Finding: OVCAP analyzed pretreatment ascites cytology from 438 women with advanced epithelial ovarian cancer. Internal and two additional-site validation cohorts yielded resistance-classification AUCs of 0.894, 0.863 and 0.828. This retrospective treatment-response study does not establish that model-guided treatment improves outcomes.
Technology: Prov-GigaPath features, TransMIL and multi-scale late fusion
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Pathology foundation-model embeddings and attention-based multiple-instance learning estimated response risk from image patches; trained multi-scale fusion combined the prediction streams.
- Test and result
- The 2019–2023 cohort comprised 367 Xuhui-campus cases split into 254 training and 113 internal-validation patients, plus 51 Pudong-campus and 20 Northern-Jiangsu validation patients. Patient-level three-fold training cross-validation selected among 15 encoders and hyperparameters. The retained multi-scale predictor was applied unchanged to the held-out cohorts. Resistance meant progression during therapy or recurrence/progression within six months after completing platinum treatment; the reported internal/external AUCs were .894/.863/.828.
- Limitation / still unknown
- The three sites represent two institutions; one additional-site cohort shares the same cancer center as development. The smallest cohort contains only 20 people. Retrospective selection of patients with evaluable outcomes, histologic concentration in high-grade serous cancer and preparation/scanner differences constrain transfer. AUCs are not treatment-benefit estimates. Attention-selected morphology and integrated single-cell associations are hypothesis-generating, not established mechanisms of resistance. Clinical vignettes and comparison with later-available kinetic biomarkers do not demonstrate prospective clinical utility.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC13330694/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: linked separately.
Review date: 21 Nov 2026. Review scope: Original model/clinical cohort, outcome definition, patient-level training selection and held-out Results; exploratory biological interpretation and clinical benefit kept bounded..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 1/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Source check: Source checked. Not independent scientific confirmation.
Finding: OCLR stemness scores and consensus clustering in 389 TCGA gastric cancers defined two subtypes; a 12-gene ML model was checked on an external cohort. Predicted immunotherapy/chemotherapy differences are in-silico and not measured treatment responses. The result is reported in Journal of Gastrointestinal Oncology. The study does not establish generalization beyond its reported setting or prospective real-world benefit.
Technology: OCLR stemness scores and consensus clustering in 389 TCGA gastric cancers defined two subtypes
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- OCLR stemness scores and consensus clustering in 389 TCGA gastric cancers defined two subtypes
- Test and result
- OCLR stemness scores and consensus clustering in 389 TCGA gastric cancers defined two subtypes; a 12-gene ML model was checked on an external cohort. Predicted immunotherapy/chemotherapy differences are in-silico and not measured treatment responses.
- Limitation / still unknown
- Independent replication and prospective real-world benefit are not established in the reviewed study.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC12598432/ · https://europepmc.org/article/MED/41220758
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Source check: Source checked. Not independent scientific confirmation.
Finding: Primary article reports multi-omics and ten-ML-algorithm work identifying bladder-cancer PANoptosis subtypes and a prognostic signature. External cohorts support survival associations; immunotherapy response is computationally inferred. This record is limited to the study result and does not establish independent replication or real-world benefit.
Technology: Ten-machine-learning-algorithm panel
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- transcriptomic/spatial data, subtype analysis and ten ML algorithms for the PANoptosis prognostic signature.
- Test and result
- Primary article reports multi-omics and ten-ML-algorithm work identifying bladder-cancer PANoptosis subtypes and a prognostic signature. External cohorts support survival associations; immunotherapy response is computationally inferred.
- Limitation / still unknown
- No prospective clinical benefit or broader external validity is established by the documented study.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://doi.org/10.32604/or.2025.064331
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 3/5 · Validation 2/5 · Novelty 3/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Source check: Source checked. Not independent scientific confirmation.
Finding: The model separated high- and low-risk groups in internal and external cohorts; external cohort comprised 87 patients. External replication and prospective utility were not established in the reviewed material.
Technology: A 3D multimodal deep-radiomics model combined pretreatment PET/CT and clinical stage to estimate five-year PFS.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- A 3D multimodal deep-radiomics model combined pretreatment PET/CT and clinical stage to estimate five-year PFS.
- Test and result
- The model separated high- and low-risk groups in internal and external cohorts; external cohort comprised 87 patients.
- Limitation / still unknown
- External replication, causal effects and prospective utility were not established in the reviewed material.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://www.frontiersin.org/journals/oncology/articles/10.3389/fonc.2022.899351/full
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.
Source check: Source checked. Not independent scientific confirmation.
Finding: TCGA cohort (230 samples) supports an SVM platinum-response classifier and LASSO-Cox survival model, with GEO used for validation. External replication and prospective utility were not established in the reviewed material.
Technology: Machine-learning signatures predict platinum response and survival in ovarian cancer.
Publication: Peer-reviewed paper · Test context: retrospective or benchmark. Catalog categories, not an evidence grade.
- AI contribution
- Machine-learning signatures predict platinum response and survival in ovarian cancer.
- Test and result
- TCGA cohort (230 samples) supports an SVM platinum-response classifier and LASSO-Cox survival model, with GEO used for validation.
- Limitation / still unknown
- External replication, causal effects and prospective utility were not established in the reviewed material.
Evidence sources and annotation context
Evidence context (descriptions follow the cited sources; test type is a catalog classification):
Evidence sources: https://pmc.ncbi.nlm.nih.gov/articles/PMC8973612/
Source checked · editorial details
The source page was checked against this entry. Independent confirmation is not assessed by this label.
Source type: paper. Paper: not linked in this catalog; this does not mean no paper exists.
Review date: 22 Nov 2026. Review scope: Primary result-bearing material for the stated method, result and evaluation, with bibliographic version information..
No follow-up recorded; this is not a claim that no follow-up exists. Follow-up review scope and date are not recorded. No source-supported relationships recorded.
Editorial assessment: Impact 2/5 · Validation 2/5 · Novelty 2/5. Impact and novelty are editorial judgments; validation follows the annotated test type where one exists. Not an evidence grade. Scoring criteria.